Biosimilars and Follow-On Biologics Market to be Stimulated by High Demand for Affordable Drugs, Reports Visiongain
27 Jul 2012 • by Natalie Aster
Patent expiry will erode blockbuster revenues in biopharma, creating many opportunities for biosimilars and related follow-on biologics. More than 20 blockbuster biologics will lose patent protection in the US by 2022.
High demand for more affordable biological drugs will stimulate the market.
New Visiongain's report “Biosimilars and Follow-On Biologics: World Market 2012-2022” investigates biosimilars (follow-on biologics). It lets assess forecasted sales at world market, therapeutic submarket and national level to 2022. The study shows potential revenues and trends to 2022, discussing data, opportunities and prospects.
This investigation gives business research and analysis with sales forecasts and opinion.
The new report gives coverage of regulatory affairs too - FDA, EMA and others - assessing trends and outlooks for biosimilar drugs. The study shows you how biopharmaceutical competition will intensify. The R&D pipeline for follow-on biological drugs is strong and promising. Also, improved drug delivery will be important from 2012. You see how and why.
Biosimilars and Follow-On Biologics: World Market 2012-2022
Published: April, 2012
Price: US$ 2.642,00
There are discussed Sandoz, Teva, Dr. Reddy's, Wockhardt and others, evaluating prospects of the industry and market.
Many commercial opportunities for biosimilars and related products exist, with high revenues possible to 2022. Product launches will change the market.
You can investigate biosimilar drugs now, discovering revenue potentials and other trends.
There are revenue forecasting, growth rates and market shares in visiongain's report.
More information can be found in the report “Biosimilars and Follow-On Biologics: World Market 2012-2022” by Visiongain.
To order the report or ask for sample pages contact [email protected]